Soleus Capital Management
Latest statistics and disclosures from Soleus Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are KRYS, TGTX, NVCR, XBI, ELV, and represent 32.34% of Soleus Capital Management's stock portfolio.
- Added to shares of these 10 stocks: ELV (+$61M), TGTX (+$58M), INSP (+$46M), TWST (+$43M), XBI (+$40M), FOLD (+$37M), NVCR (+$35M), INDV (+$35M), MDGL (+$28M), ANIP (+$27M).
- Started 18 new stock positions in GMED, GUTS, BLTE, HROW, RAPT, QURE, NBIX, FOLD, LQDA, OLMA. Lb Pharmaceuticals, INDV, RAPP, KOD, MNKD, GSK, VTGN, MBX.
- Reduced shares in these 10 stocks: CELC (-$91M), STAA (-$67M), ALNY (-$42M), GRFS (-$32M), URGN (-$30M), , UTHR (-$25M), SRDX (-$23M), HUM (-$20M), ASND (-$15M).
- Sold out of its positions in ABVX, ADPT, ASND, AXSM, BCYC, ENOV, CTMX, DNLI, EWTX, HUM.
- Soleus Capital Management was a net buyer of stock by $114M.
- Soleus Capital Management has $2.0B in assets under management (AUM), dropping by 31.54%.
- Central Index Key (CIK): 0001802630
Tip: Access up to 7 years of quarterly data
Positions held by Soleus Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Soleus Capital Management
Soleus Capital Management holds 88 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Krystal Biotech (KRYS) | 9.1 | $180M | +10% | 1.0M | 176.53 |
|
| Tg Therapeutics (TGTX) | 7.0 | $139M | +71% | 3.8M | 36.12 |
|
| Novocure Ord Shs (NVCR) | 6.3 | $125M | +39% | 9.6M | 12.92 |
|
| Spdr Series Trust S&p Biotech Put Option (XBI) | 5.8 | $115M | +53% | 1.2M | 100.20 |
|
| Anthem (ELV) | 4.2 | $84M | +270% | 260k | 323.12 |
|
| Beta Bionics (BBNX) | 3.9 | $77M | 3.9M | 19.87 |
|
|
| United Therapeutics Corporation (UTHR) | 3.2 | $63M | -28% | 150k | 419.21 |
|
| Terns Pharmaceuticals (TERN) | 3.1 | $61M | 8.1M | 7.51 |
|
|
| Celcuity (CELC) | 2.9 | $58M | -60% | 1.2M | 49.40 |
|
| Inspire Med Sys (INSP) | 2.7 | $54M | +568% | 728k | 74.20 |
|
| Twist Bioscience Corp (TWST) | 2.6 | $53M | +426% | 1.9M | 28.14 |
|
| Argenx Se Sponsored Adr (ARGX) | 2.6 | $51M | +61% | 69k | 737.56 |
|
| Organogenesis Hldgs (ORGO) | 2.6 | $51M | 12M | 4.22 |
|
|
| BioMarin Pharmaceutical (BMRN) | 2.4 | $48M | 890k | 54.16 |
|
|
| Cidara Therapeutics Com New (CDTX) | 2.4 | $47M | +6% | 494k | 95.76 |
|
| Praxis Precision Medicines I Com New (PRAX) | 2.3 | $46M | -11% | 859k | 53.00 |
|
| Amicus Therapeutics (FOLD) | 1.9 | $37M | NEW | 4.7M | 7.88 |
|
| Indivior Ord (INDV) | 1.8 | $35M | NEW | 1.5M | 24.11 |
|
| Madrigal Pharmaceuticals (MDGL) | 1.6 | $31M | +754% | 68k | 458.66 |
|
| Biosante Pharmaceuticals (ANIP) | 1.6 | $31M | +570% | 340k | 91.60 |
|
| Syndax Pharmaceuticals (SNDX) | 1.6 | $31M | +84% | 2.0M | 15.38 |
|
| Axogen (AXGN) | 1.6 | $31M | +18% | 1.7M | 17.84 |
|
| Neuropace (NPCE) | 1.5 | $31M | +27% | 3.0M | 10.31 |
|
| Grifols S A Sp Adr Rep B Nvt (GRFS) | 1.3 | $25M | -56% | 2.5M | 9.96 |
|
| Geron Corporation (GERN) | 1.2 | $24M | +7% | 17M | 1.37 |
|
| Nurix Therapeutics (NRIX) | 1.1 | $22M | 2.4M | 9.24 |
|
|
| Integra Lifesciences Hldgs C Com New (IART) | 1.0 | $21M | +3% | 1.4M | 14.33 |
|
| Neurocrine Biosciences (NBIX) | 1.0 | $19M | NEW | 138k | 140.38 |
|
| Anaptysbio Inc Common (ANAB) | 1.0 | $19M | +95% | 626k | 30.62 |
|
| Edap Tms S A Sponsored Adr (EDAP) | 0.8 | $17M | 7.3M | 2.29 |
|
|
| Pharvaris N V (PHVS) | 0.8 | $16M | -11% | 647k | 24.95 |
|
| Vericel (VCEL) | 0.8 | $16M | +877% | 498k | 31.47 |
|
| C4 Therapeutics Com Stk (CCCC) | 0.8 | $16M | 7.1M | 2.22 |
|
|
| Belite Bio Sponsored Ads (BLTE) | 0.8 | $16M | NEW | 210k | 74.00 |
|
| Veracyte (VCYT) | 0.7 | $15M | -41% | 422k | 34.33 |
|
| Rapt Therapeutics Com New (RAPT) | 0.7 | $14M | NEW | 538k | 25.79 |
|
| Urogen Pharma (URGN) | 0.7 | $14M | -68% | 679k | 19.95 |
|
| Staar Surgical Com Par $0.01 (STAA) | 0.7 | $13M | -83% | 500k | 26.87 |
|
| Sionna Therapeutics (SION) | 0.6 | $12M | +9% | 414k | 29.41 |
|
| Cg Oncology (CGON) | 0.6 | $12M | +87% | 290k | 40.28 |
|
| Uniqure Nv SHS (QURE) | 0.6 | $12M | NEW | 200k | 58.37 |
|
| Quidel Corp (QDEL) | 0.6 | $11M | +115% | 375k | 29.45 |
|
| Mirum Pharmaceuticals (MIRM) | 0.5 | $11M | -50% | 149k | 73.31 |
|
| Adma Biologics (ADMA) | 0.5 | $11M | +321% | 738k | 14.66 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.5 | $10M | 6.3M | 1.62 |
|
|
| Globus Med Cl A (GMED) | 0.5 | $10M | NEW | 176k | 57.27 |
|
| GSK Sponsored Adr (GSK) | 0.5 | $9.5M | NEW | 220k | 43.16 |
|
| Rigel Pharmaceuticals (RIGL) | 0.5 | $9.3M | -49% | 330k | 28.33 |
|
| Evolus (EOLS) | 0.4 | $8.9M | -31% | 1.5M | 6.14 |
|
| Verastem Com New (VSTM) | 0.4 | $8.3M | 936k | 8.83 |
|
|
| Arcellx Common Stock (ACLX) | 0.4 | $8.2M | -18% | 100k | 82.10 |
|
| Nuvalent Inc-a (NUVL) | 0.4 | $7.6M | -29% | 88k | 86.48 |
|
| Alnylam Pharmaceuticals (ALNY) | 0.4 | $7.0M | -85% | 15k | 456.00 |
|
| Jade Biosciences Com New (JBIO) | 0.3 | $6.9M | 797k | 8.63 |
|
|
| Lb Pharmaceuticals Com Shs | 0.3 | $6.3M | NEW | 400k | 15.79 |
|
| Olema Pharmaceuticals (OLMA) | 0.3 | $6.1M | NEW | 620k | 9.79 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.3 | $5.8M | -41% | 150k | 38.83 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.3 | $5.7M | -34% | 140k | 40.99 |
|
| Mbx Biosciences (MBX) | 0.2 | $4.8M | NEW | 275k | 17.50 |
|
| Erasca (ERAS) | 0.2 | $4.7M | 2.2M | 2.18 |
|
|
| Eton Pharmaceuticals (ETON) | 0.2 | $4.3M | -29% | 200k | 21.73 |
|
| Ceribell (CBLL) | 0.2 | $4.1M | +620% | 360k | 11.49 |
|
| Harrow Health (HROW) | 0.2 | $4.1M | NEW | 86k | 48.18 |
|
| Fractyl Health (GUTS) | 0.2 | $4.0M | NEW | 2.5M | 1.59 |
|
| Jasper Therapeutics Com New (JSPR) | 0.2 | $3.6M | 1.5M | 2.38 |
|
|
| Inspiremd (NSPR) | 0.2 | $3.5M | -22% | 1.5M | 2.41 |
|
| Akero Therapeutics (AKRO) | 0.2 | $3.4M | 71k | 47.48 |
|
|
| Ideaya Biosciences (IDYA) | 0.1 | $2.7M | -60% | 100k | 27.21 |
|
| Tango Therapeutics (TNGX) | 0.1 | $2.5M | -58% | 300k | 8.40 |
|
| Crescent Biopharma (CBIO) | 0.1 | $2.4M | -50% | 200k | 11.89 |
|
| Rapport Therapeutics (RAPP) | 0.1 | $2.4M | NEW | 80k | 29.70 |
|
| Orthopediatrics Corp. (KIDS) | 0.1 | $2.4M | +184% | 128k | 18.53 |
|
| Iovance Biotherapeutics (IOVA) | 0.1 | $2.1M | -70% | 977k | 2.17 |
|
| Calcimedica Com New (CALC) | 0.1 | $2.1M | -12% | 684k | 3.08 |
|
| Vistagen Therapeutics Ord (VTGN) | 0.1 | $2.0M | NEW | 550k | 3.55 |
|
| Mannkind Corp Com New (MNKD) | 0.1 | $1.6M | NEW | 300k | 5.37 |
|
| Immunic (IMUX) | 0.1 | $1.4M | -78% | 1.6M | 0.88 |
|
| Adverum Biotechnologies Com New (ADVM) | 0.1 | $1.3M | 287k | 4.53 |
|
|
| Liquidia Corporation Com New (LQDA) | 0.1 | $1.1M | NEW | 50k | 22.74 |
|
| Essa Pharma Com New (EPIX) | 0.0 | $833k | +92% | 4.4M | 0.19 |
|
| Myomo Com New (MYO) | 0.0 | $628k | 704k | 0.89 |
|
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.0 | $617k | -50% | 300k | 2.06 |
|
| Tectonic Therapeutic (TECX) | 0.0 | $392k | -67% | 25k | 15.69 |
|
| Insmed Com Par $.01 (INSM) | 0.0 | $367k | -96% | 2.6k | 144.01 |
|
| Septerna (SEPN) | 0.0 | $344k | -75% | 18k | 18.81 |
|
| Kodiak Sciences (KOD) | 0.0 | $322k | NEW | 20k | 16.37 |
|
| Trevi Therapeutics (TRVI) | 0.0 | $229k | -96% | 25k | 9.15 |
|
| Delcath Sys Com New (DCTH) | 0.0 | $108k | -60% | 10k | 10.75 |
|
Past Filings by Soleus Capital Management
SEC 13F filings are viewable for Soleus Capital Management going back to 2019
- Soleus Capital Management 2025 Q3 filed Nov. 14, 2025
- Soleus Capital Management 2025 Q2 filed Aug. 15, 2025
- Soleus Capital Management 2025 Q1 filed May 15, 2025
- Soleus Capital Management 2024 Q4 filed Feb. 14, 2025
- Soleus Capital Management 2024 Q3 filed Nov. 14, 2024
- Soleus Capital Management 2024 Q2 filed Aug. 14, 2024
- Soleus Capital Management 2024 Q1 filed May 15, 2024
- Soleus Capital Management 2023 Q4 filed Feb. 14, 2024
- Soleus Capital Management 2023 Q3 filed Nov. 14, 2023
- Soleus Capital Management 2023 Q2 filed Aug. 14, 2023
- Soleus Capital Management 2023 Q1 filed May 15, 2023
- Soleus Capital Management 2022 Q4 filed Feb. 14, 2023
- Soleus Capital Management 2022 Q3 filed Nov. 14, 2022
- Soleus Capital Management 2022 Q2 filed Aug. 15, 2022
- Soleus Capital Management 2022 Q1 filed May 16, 2022
- Soleus Capital Management 2021 Q4 filed Feb. 14, 2022